Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 68 for “"Lopinavir"”.
-
Didanosine and lopinavir : non–conventional solid–states
… the antiretroviral (ARV) agents, didanosine and lopinavir, are reported. The polymorphs were prepared from recrystallisation and the glasses from cooling of the melt. These products were then characterised by means of thermal, absorption and diffraction analyses and compared to the raw material …
-
FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR: BINDING, UPTAKE AND EFFLUX
… limiting placental passage and fetal exposure to lopinavir. These factors include lopinavir plasma protein binding and uptake, cellular binding, and efflux of lopinavir in the placental trophoblast cells. First, we determined the unbound fraction of lopinavir in cord blood and characterized the …
-
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
… antiretroviraler Therapie (ART) in Südafrika die Lopinavir (LPV) und Efavirenz (EFV) Serumkonzentrationen in der klinischen Routine zu messen und Risikofaktoren für unzureichende Medikamentenexposition zu identifizieren. Zu diesem Zweck wurde eine prospektive Erhebung im Tygerberg Hospital, …
-
The pharmacologenetics of lopinavir in a cohort of black African HIV/AIDS patients
… (PIs). In South Africa PIs, specifically lopinavir (LPV) boosted with another PI, ritonavir (RTV) are used in second-line ARV regimens along with a backbone of 2 NRTIs. The use of ARVs is not without issues - patients often experience side-effects to the drugs such as nausea, diarrhoea, …
-
PXR-mediated Regulation of Placental Drug Transporters Impact on Fetal Exposure to Lopinavir
… transporter levels on fetal drug accumulation of lopinavir, a key antiretroviral used extensively in pregnant women. We examined the role of the nuclear receptor at the placental interface in PXR knockout and wildtype mice. Pegnenolone-16-á-carbonitrile (PCN) treatment failed to induce PXR and …
-
Enhancement of the Placental Transmission of Lopinavir Using a Transporter Targeted Prodrug Strategy
Lopinavir (LPV) is a potent protease inhibitor specific for HIV-1. However, LPV has poor placental penetration due to substrate activity for efflux transporter by P-glycoprotein (P-gp). Since fatty acid transporters are highly expressed in the placenta during pregnancy, we designed fatty acid ester …
-
Prodrug Approach to Improve Oral and Brain Absorption of HIV Protease Inhibitor, Lopinavir
… thereby enhancing oral and brain absorption of lopinavir (LPV). Oral absorption of LPV is severly limited due to low aqueous solubility, intestinal efflux by P-gp and MRP2 and extensive hepatic metabolism (CYP3A4 enzymes). Furthermore, brain LPV absorption is poor due to high efflux by P-gp and …
-
Triglyceride values after six months of lopinavir/ritonavir therapy as an indicator for pancreatitis risk
… virus (HIV) - are known to induce HTG. Lopinavir/ritonavir (LPV/r) is the PI combination in a single dosage form that was relevant to this study. The primary aim of this study was to investigate the risk of pancreatitis after the first six months of LPV/r therapy. The study included …
-
Einfluss des Therapeutischen Drug Monitoring von Lopinavir auf das klinische Management bei HIV-infizierten Kindern in Südafrika
… Hierbei wurden mittels HPLC gemessene Lopinavir(LPV)-Serumspiegel und die individuelle Situation der Patienten im klinischen Kontext ausgewertet. Ziel der Arbeit war, die Bedeutung des LPV-TDM in der antiretroviralen Therapie (ART) herauszuarbeiten und so Rückschlüsse über den Einsatz …
-
Lopinavir/ritonavir cápsulas : perfil de dissolução in vitro baseado nos dados in vivo, estudos de estabilidade térmica e metodologia analítica
Kaletra® (lopinavir e ritonavir) é uma combinação fixa de dois inibidores da protease do vírus da imunodeficiência humana (VIH) indicada para o tratamento da infecção pelo VIH em associação com outros anti-retrovirais. Esta classe de fármacos inibe a protease do VIH evitando a clivagem da …
-
Blood levels of selective antiretroviral drugs over a period of time, in Sprague-Dawley rats
… 5 mg/kg/day (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day, (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day and verapamil 5 mg/kg/day (n = 18). Treatment duration varied from one day (single dose), 7 or 21 days. Blood samples were collected after decapitation on days 1, 7 and …
-
Drug Monitoring von Lopinavir, Efavirenz und Nevirapin im Rahmen der antiretroviralen Kombinationstherapie bei Kindern und Jugendlichen mit HIV-Infektion in Kapstadt, Südafrika
Der Nutzen von Therapeutischem Drug Monitoring (TDM) bei der Behandlung von HIV-infizierten Kindern in Ländern mit geringen finanziellen Ressourcen ist bisher nicht gründlich erforscht worden. Pharmakokinetische Studien antiretroviraler Medikamente haben bei Kindern eine hohe intra- und …
-
The effects of HIV-1 viral protein r (vpr) and anti-retroviral drugs in the brain: Implications in HIV-1 associated neurocognitive disorders
… vivo in mice. We found that antiretroviral drugs lopinavir/ritonavir produce neuroinflammatory cytokines/chemokines (IL 6 and IL-8) and oxidative stress in vitro. Neuroplasticity proteins and antioxidant system were also perturbed by lopinavir/ritonavir treatment in mice brain which were prevented …
-
Untersuchungen zum Therapeutischen Drug Monitoring von Nevirapin, Efavirenz und Lopinavir im Rahmen der antiretroviralen Kombinationstherapie bei Patienten mit HIV-Infektion in Mwanza/Tansania
… Medikamente Nevirapin, Efavirenz und Lopinavir bei 124 ambulanten HIV-Patienten der HIV-Ambulanz des Bugando Hospitals in Mwanza (Tansania) bestimmt. Sechs Patienten mussten ausgeschlossen werden, so dass letztlich bei 118 Patienten überprüft wurde, welche Serumspiegel sich zu zufällig …
-
Impact of Diabetes on Drug Disposition Mechanisms in Pregnancy
… fetal exposure to the Mdr1 and Cyp3a2 substrate lopinavir was substantially lower than controls post-administration and data supporting enhanced lopinavir metabolite formation were obtained. Placental drug efflux transporters were also examined in this lopinavir study. Elevated placental Mdr1b …
-
North-South collaboration in clinical pharmacological research of HIV treatment.
… with a higher than standard dose of the new lopinavir/ritonavir tablets in combination with rifampicin. An adequately powered prospective study in HIV-tuberculosis co-infected patients is needed to investigate the consequence of inferior lopinavir exposure due to non-adjusted doses of …
-
Endogenous retroviral proteins as potential drug targets for merlin-deficient tumours
… protease inhibitors Ritonavir, Atazanavir and Lopinavir which could be potentially repurposed for the treatment of Merlin-deficient schwannoma and grade I meningioma. Ritonavir and Lopinavir effectively decreased the proliferation of Merlin-deficient primary schwannoma cells at concentrations …
-
Μελέτη του μεταβολισμού του παράγοντα ενεργοποίησης αιμοπεταλίων (PAF) σε ανθρώπινα μεσαγγειακά κύτταρα - επίδραση αντι-φλεγμονοδών, αντι-καρκινικών και αντι-ιϊκών παραγόντων στην δράση του PAF και των ενζύμων του μεταβολισμού του
… inhibitory effect against PAF-activity. Lopinavir -r and Tenofovir DF also inhibited the biosynthetic enzymes PAF-CPT and Lyso-PAF-AT, while lopinavir-r induced PAF-AH activity of HMC.
-
Developing novel drug combinations for treatment of invasive fungal infections
… resistant C. auris. The HIV protease inhibitors (lopinavir and ritonavir) were identified as potent enhancers to the antifungal activity of azole drugs (fluconazole, voriconazole and itraconazole). We confirmed that lopinavir and ritonavir have the capability to interfere with fungal efflux pump …
-
Drug resistance mechanisms and drug design strategies for human immunodeficiency virus and hepatitis c virus proteases
… method is the modification of a current drug, lopinavir. The potency of the lopinavir analog against the MDR HIV-1 protease increases. The other method is the identification of a novel HIV-1 protease inhibitor scaffold to increase the structural diversity of inhibitors. In the HCV section, the …
Page 1 of 4